US 12,233,075 B2
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
Michelle R. Simpson-Abelson, Lithia, FL (US); Christopher Mosychuk, St. Petersburg, FL (US); and Michael T. Lotze, Pittsburgh, PA (US)
Assigned to Iovance Biotherapeutics, Inc., San Carlos, CA (US)
Filed by Iovance Biotherapeutics, Inc., San Carlos, CA (US)
Filed on Jun. 9, 2022, as Appl. No. 17/836,998.
Application 17/836,998 is a continuation of application No. 16/462,056, granted, now 11,401,507, previously published as PCT/US2017/062219, filed on Nov. 17, 2017.
Claims priority of provisional application 62/460,441, filed on Feb. 17, 2017.
Claims priority of provisional application 62/423,750, filed on Nov. 17, 2016.
Prior Publication US 2023/0106186 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 31/661 (2006.01); A61K 35/17 (2015.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 31/661 (2013.01) [A61K 35/17 (2013.01); A61K 38/2013 (2013.01); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); A61P 35/00 (2018.01); C12N 5/0638 (2013.01); C12N 2501/06 (2013.01); C12N 2501/065 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2501/998 (2013.01)] 20 Claims
 
1. A population of remnant tumor infiltrating lymphocytes (rTILs) for adoptive T cell therapy, the population of cells having, on average, two or more of the following:
a. CD69 median fluorescence intensity (MFI) expression of 2000 or higher in CD4+ cells or 4000 or higher in CD8+ cells;
b. LAG3 median fluorescence intensity (MFI) expression of 100 or lower in CD4+ cells or 250 or lower in CD8+ cells;
c. TIM3 median fluorescence intensity (MFI) expression of 15 or lower in CD4+ cells or 1000 or lower in CD8+ cells;
d. CD56 median fluorescence intensity (MFI) expression of 2 or lower; or
e. a TCRvβ diversity score of 0.5 or higher.